Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-18T06:12:12.490Z Has data issue: false hasContentIssue false

Co-Produced Research Priorities for Metabolic Interventions in Severe Mental Illness: A James Lind Alliance Priority Setting Partnership

Published online by Cambridge University Press:  30 June 2026

Dina Farran
Affiliation:
King’s College London, London, United Kingdom
Toby Pillinger
Affiliation:
King’s College London, London, United Kingdom
Fiona Gaughran
Affiliation:
King’s College London, London, United Kingdom
Khalida Ismail
Affiliation:
King’s College London, London, United Kingdom
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Aims:

Metabolic dysfunction is a major driver of excess morbidity and premature mortality in people with severe mental illness (SMI). Converging evidence suggests that disturbances in brain energy metabolism may contribute to psychiatric symptoms in SMI. Despite growing interest in metabolic psychiatry, research in this area has largely been shaped by academic priorities, with limited structured input from people with lived experience, carers, or front-line professionals regarding which metabolic interventions and outcomes matter most to them. Consequently, evidence to guide metabolic approaches that improve physical and mental health outcomes in SMI remains fragmented and poorly aligned with stakeholder priorities. The James Lind Alliance (JLA) Priority Setting Partnership (PSP) for Metabolic Interventions in SMI was established to identify and prioritise research uncertainties that matter most to people with lived experience, carers, and professionals.

Methods:

The PSP followed the five-stage JLA methodology: defining scope, gathering questions, refining and verifying uncertainties, interim prioritisation, and a final consensus workshop. An international open-call survey collected research questions from people with lived experience of SMI, carers, and professionals. Submissions were thematically synthesised into summary questions and checked against evidence through an umbrella review of meta-analyses to identify unanswered uncertainties. Verified uncertainties were ranked in an online survey. A structured, facilitated online workshop using nominal group techniques produced the final Top 10 priorities.

Results:

In the first survey, 456 participants submitted 1,439 research questions. After removal of out-of-scope submissions and qualitative synthesis, 51 summary questions across 13 thematic domains were generated. Evidence checking identified two questions as adequately answered, leaving 49 verified uncertainties. In the interim prioritisation survey, 317 participants ranked these uncertainties, producing a shortlist of 19 questions. Thirty stakeholders (16 with lived experience or carers; 14 professionals) took part in the final online workshop. The resulting Top 10 priorities focused on dietary interventions, combined lifestyle strategies, GLP-1 receptor agonists for medication-related weight gain and potential mental health benefits, micronutrient deficiencies, physical activity, metabolic effects of psychiatric medications beyond weight gain, gut-brain mechanisms, brain changes associated with metabolic improvement, and the role of ketone bodies in symptom improvement and remission.

Conclusion:

This PSP establishes the first stakeholder-driven research agenda for metabolic psychiatry in SMI, identifying priorities that integrate diet, physical activity, pharmacological adjuncts, and mechanistic pathways linking metabolic and mental health. The Top 10 priorities provide a translational roadmap for future trials, mechanistic studies, and implementation research aimed at reducing cardiometabolic inequalities and improving psychiatric outcomes in SMI.

This work was funded by UK Research and Innovation (UKRI) through the Hub for Metabolic Psychiatry.

Information

Type
Research
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Royal College of Psychiatrists
Submit a response

eLetters

No eLetters have been published for this article.